261 related articles for article (PubMed ID: 35222408)
1. A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis.
Chen S; Zhan S; Hua C; Tang Y; Cheng H
Front Immunol; 2022; 13():825796. PubMed ID: 35222408
[TBL] [Abstract][Full Text] [Related]
2. The complicated use of dupilumab in the treatment of atypical generalized pemphigus Erythematous: A report of two cases.
Chen J; Chen S; Wu X; Jiang X; Wang Y; Cheng H
Hum Vaccin Immunother; 2023 Dec; 19(1):2151290. PubMed ID: 36798973
[TBL] [Abstract][Full Text] [Related]
3. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Russo R; Cozzani E; Gasparini G; Parodi A
Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
[TBL] [Abstract][Full Text] [Related]
4. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
5. Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris.
Rico MJ; Benning C; Weingart ES; Streilein RD; Hall RP
Br J Dermatol; 1999 Jun; 140(6):1079-86. PubMed ID: 10354074
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 4 inhibition as a potential therapeutic in pemphigus.
Tavakolpour S; Tavakolpour V
Cytokine; 2016 Jan; 77():189-95. PubMed ID: 26440137
[TBL] [Abstract][Full Text] [Related]
7. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris.
Satyam A; Khandpur S; Sharma VK; Sharma A
Immunol Invest; 2009; 38(6):498-509. PubMed ID: 19811408
[TBL] [Abstract][Full Text] [Related]
8. Divergent in situ expression of IL-31 and IL-31RA between bullous pemphigoid and pemphigus vulgaris.
Ergun EZ; Aoki R; Horváth ON; Hartmann D; Satoh TK; Calabrese L; Aksu AEK; Gürel MS; Manav V; Flaig MJ; Sárdy M; Ruzicka T; French LE; Bağcı IS
Exp Dermatol; 2023 Sep; 32(9):1412-1419. PubMed ID: 37260420
[TBL] [Abstract][Full Text] [Related]
9. Potential Indications of Dupilumab in Th-2 Inflammatory Disease.
Ilaria P; Nevena S; Ersilia T; Nicoletta B; Federica T; Di Fraia M; Agniezska D; Concetta P
Rev Recent Clin Trials; 2024; 19(1):53-61. PubMed ID: 38141197
[TBL] [Abstract][Full Text] [Related]
10. Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis.
Okune M; Okiyama N; Fukuzono M; Sasaki K; Nomura T
J Dermatol; 2022 May; 49(5):556-559. PubMed ID: 35224748
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
12. The role of T cells in pemphigus vulgaris and bullous pemphigoid.
Fang H; Li Q; Wang G
Autoimmun Rev; 2020 Nov; 19(11):102661. PubMed ID: 32942041
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
14. Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis.
Bakker DS; van der Wal MM; Heeb LEM; Giovannone B; Asamoah M; Delemarre EM; Drylewicz J; Nierkens S; Boyman O; de Bruin-Weller MS; Thijs JL; van Wijk F
J Invest Dermatol; 2021 Aug; 141(8):1943-1953.e13. PubMed ID: 33610558
[TBL] [Abstract][Full Text] [Related]
15. Drug evaluation review: dupilumab in atopic dermatitis.
Hamilton JD; Ungar B; Guttman-Yassky E
Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab: Basic aspects and applications to allergic diseases.
Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab for the treatment of asthma.
Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
[TBL] [Abstract][Full Text] [Related]
18. Rosacea associated with dupilumab therapy.
Heibel HD; Hendricks AJ; Foshee JP; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
[No Abstract] [Full Text] [Related]
19. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
